SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

FluMist

AZN·ASTRAZENECA PLC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already on the market since 2003; the 2026-2027 seasonal formulation is currently available.
Why 3/10
No hard, dated binary catalyst is scheduled in the next ~12 months. FluMist is an already-approved, marketed seasonal product with no pending PDUFA, pivotal readout, or AdComm. The annual strain update and seasonal availability are routine commercial events, not binary catalysts. ImpactScore is 3 because this is an approved product with no pending regulatory decision and it represents a very small fraction of AstraZeneca's diversified ~$62B revenue base.
Actionable Insight NEUTRAL

FluMist is an already-approved, seasonal product with no binary regulatory catalysts on the horizon. The key commercial metric to watch is whether FluMist Home (at-home delivery) drives meaningful market share gains in the 2026-2027 flu season, but given FluMist's small contribution to AstraZeneca's ~$62B revenue base, even a strong season would barely move the stock. The next meaningful event would be the 2027-2028 strain composition update, which is routine and non-binary.

Price Chart

Loading chart...

Executive Summary

FluMist is AstraZeneca's live attenuated influenza vaccine delivered as a nasal spray, the only needle-free flu vaccine option in the US. Originally approved by the FDA in 2003 and developed by MedImmune (acquired by AstraZeneca in 2007), it is indicated for ages 2 through 49. A landmark FDA approval in September 2024 allowed self- or caregiver-administration, and AstraZeneca launched FluMist Home (at-home mail delivery) for the 2025-2026 season. The 2026-2027 season formulation is now available. However, FluMist is a very small part of AstraZeneca's business: vaccines and immune therapies combined generated only ~$846M in 2025 against total company revenue of ~$58.7B. With no pending regulatory binary catalysts, FluMist is a steady but non-material contributor to AstraZeneca's diversified portfolio.

How It Works

FluMist is a live attenuated influenza vaccine (LAIV) delivered as a nasal spray. It contains weakened live influenza viruses that are designed to replicate in the cooler temperature of the nose, stimulating the body's immune system to produce antibodies against the flu without causing illness. Because it is sprayed into the nose rather than injected with a needle, it mimics the natural route of flu infection and triggers both systemic and local (nasal) immune responses. It is reformulated each year to match the influenza strains expected to circulate in the upcoming season.

Trial Status

FluMist is an FDA-approved, commercially marketed product. It was originally approved in June 2003, with a key label expansion in September 2024 allowing self- or caregiver-administration. The 2026-2027 seasonal formulation is currently available in the US through healthcare settings and via FluMist Home at-home delivery.

The Two-Sided Case

▲ Bull Case4
FluMist is the only FDA-approved nasal spray flu vaccine in the US, giving it a unique product differentiation versus all injectable competitors.
The 2024 FDA approval for self- or caregiver-administration and the 2025 launch of FluMist Home (at-home mail delivery) opened a new convenience channel that could expand the flu vaccine market and grow FluMist's share.
FluMist has been on the market since 2003 with a well-established safety and efficacy profile, and it is reformulated annually to match circulating strains per WHO/CDC recommendations.
AstraZeneca's overall analyst consensus is bullish (28 Buy/Strong Buy vs 6 Hold/0 Sell) with a mean price target of ~$206.66, implying ~18.5% upside from the recent $174.40 close.
▼ Bear Case4
FluMist is a tiny revenue contributor within AstraZeneca's massive ~$62B portfolio; vaccines and immune therapies combined were only ~$846M in 2025, so even strong FluMist sales barely move the needle for AZN stock.
Competition in the flu vaccine market is intense and growing: Sanofi (Fluzone, Fluad), CSL Seqirus (Flucelvax, Afluria), and emerging mRNA flu vaccines from Moderna and Pfizer all compete for market share.
FluMist has a restricted age indication (2-49 years) and is not recommended for certain populations (pregnant women, immunocompromised), limiting its addressable market versus injectable flu vaccines that cover all ages 6 months+.
The self-administration approval (2024) and FluMist Home launch (2025) are past catalysts already priced in; no new binary regulatory events are scheduled.

Upcoming Catalysts

  • No binary regulatory catalysts are scheduled. The product is already approved and commercialized. Routine seasonal updates (strain composition for 2027-2028) occur annually but are not stock-moving events for a company of AstraZeneca's size.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ASTRAZENECA PLC 6-K AZN ·Originating report

Sources · 9

Hover a chip for the title
1 astrazeneca-us.com2 fda.gov3 astrazeneca.com4 sec.gov5 fda.gov6 statista.com7 stockanalysis.com8 cdc.gov9 businesswire.com